25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Marinus Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyze Marinus Pharmaceuticals Inc together

I guess you are interested in Marinus Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Marinus Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Marinus Pharmaceuticals Inc

I send you an email if I find something interesting about Marinus Pharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of Marinus Pharmaceuticals Inc (30 sec.)










1.2. What can you expect buying and holding a share of Marinus Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$-0.83
Expected worth in 1 year
$-2.70
How sure are you?
22.5%

+ What do you gain per year?

Total Gains per Share
$-1.87
Return On Investment
-112.0%

For what price can you sell your share?

Current Price per Share
$1.67
Expected price per share
$1.54 - $5.5704
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Marinus Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)
$1.67
Intrinsic Value Per Share
$-21.34 - $-14.91
Total Value Per Share
$-22.17 - $-15.74

2.2. Growth of Marinus Pharmaceuticals Inc (5 min.)




Is Marinus Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?-$47.3m$85.1m-$83.2m-4,425.2%

How much money is Marinus Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$37.3m-$7.2m-$30m-80.4%
Net Profit Margin-494.6%431.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Marinus Pharmaceuticals Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#935 / 960

Most Revenue
#308 / 960

Most Profit
#808 / 960

Most Efficient
#648 / 960
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Marinus Pharmaceuticals Inc?

Welcome investor! Marinus Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Marinus Pharmaceuticals Inc.

First you should know what it really means to hold a share of Marinus Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Marinus Pharmaceuticals Inc is $1.67. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Marinus Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Marinus Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.83. Based on the TTM, the Book Value Change Per Share is $-0.47 per quarter. Based on the YOY, the Book Value Change Per Share is $0.24 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Marinus Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.63-37.6%-0.66-39.6%-0.13-7.5%-0.40-23.7%-0.27-15.9%
Usd Book Value Change Per Share-0.54-32.4%-0.47-28.0%0.2414.3%-0.08-5.0%-0.02-1.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.54-32.4%-0.47-28.0%0.2414.3%-0.08-5.0%-0.02-1.4%
Usd Price Per Share1.17-7.28-7.10-8.09-6.85-
Price to Earnings Ratio-0.47--2.71--1.95--4.33--8.52-
Price-to-Total Gains Ratio-2.16--47.88--5.67--22.88--34.40-
Price to Book Ratio-1.41-3.05-5.31-7.98-8.06-
Price-to-Total Gains Ratio-2.16--47.88--5.67--22.88--34.40-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.67
Number of shares598
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.47-0.08
Usd Total Gains Per Share-0.47-0.08
Gains per Quarter (598 shares)-279.66-50.09
Gains per Year (598 shares)-1,118.63-200.38
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1119-11290-200-210
20-2237-22480-401-410
30-3356-33670-601-610
40-4475-44860-802-810
50-5593-56050-1002-1010
60-6712-67240-1202-1210
70-7830-78430-1403-1410
80-8949-89620-1603-1610
90-10068-100810-1803-1810
100-11186-112000-2004-2010

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%1.019.00.05.0%1.039.00.02.5%1.045.01.02.1%
Book Value Change Per Share0.04.00.00.0%2.010.00.016.7%5.015.00.025.0%9.031.00.022.5%11.033.03.023.4%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.047.00.0%
Total Gains per Share0.04.00.00.0%2.010.00.016.7%5.015.00.025.0%9.031.00.022.5%11.033.03.023.4%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Marinus Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.541-0.468-13%0.238-327%-0.084-85%-0.023-96%
Book Value Per Share---0.8300.042-2087%1.545-154%1.140-173%0.936-189%
Current Ratio--2.2833.951-42%7.413-69%6.902-67%9.185-75%
Debt To Asset Ratio--1.5441.073+44%0.612+152%0.537+187%0.364+325%
Debt To Equity Ratio---2.969-100%1.666-100%2.344-100%1.298-100%
Dividend Per Share----0%-0%-0%-0%
Eps---0.628-0.661+5%-0.126-80%-0.396-37%-0.266-58%
Free Cash Flow Per Share---0.541-0.534-1%-0.5390%-0.403-25%-0.255-53%
Free Cash Flow To Equity Per Share---0.851-0.490-42%-0.114-87%-0.083-90%-0.002-100%
Gross Profit Margin--1.0001.0020%1.209-17%1.042-4%1.021-2%
Intrinsic Value_10Y_max---14.912--------
Intrinsic Value_10Y_min---21.344--------
Intrinsic Value_1Y_max---1.091--------
Intrinsic Value_1Y_min---1.964--------
Intrinsic Value_3Y_max---3.586--------
Intrinsic Value_3Y_min---6.086--------
Intrinsic Value_5Y_max---6.452--------
Intrinsic Value_5Y_min---10.382--------
Market Cap91990280.000+27%66764991.150410083617.648-84%390958690.000-83%447168559.530-85%378301464.765-82%
Net Profit Margin---4.447-4.946+11%4.310-203%-8.851+99%-4.4250%
Operating Margin---3.759-4.423+18%5.356-170%-8.397+123%-4.198+12%
Operating Ratio--4.7595.416-12%7.322-35%13.145-64%6.572-28%
Pb Ratio-2.013-43%-1.4103.051-146%5.314-127%7.976-118%8.055-118%
Pe Ratio-0.665-43%-0.466-2.710+482%-1.955+320%-4.333+830%-8.520+1729%
Price Per Share1.670+30%1.1707.283-84%7.098-84%8.086-86%6.852-83%
Price To Free Cash Flow Ratio-0.772-43%-0.541-3.515+550%-3.471+542%-3.088+471%-10.113+1771%
Price To Total Gains Ratio-3.089-43%-2.164-47.883+2112%-5.665+162%-22.878+957%-34.397+1489%
Quick Ratio--1.8994.113-54%8.449-78%7.142-73%10.188-81%
Return On Assets---0.411-0.275-33%-0.014-97%-0.174-58%-0.162-61%
Return On Equity----0.7740%-0.0960%-0.7390%-0.4650%
Total Gains Per Share---0.541-0.468-13%0.238-327%-0.084-85%-0.023-96%
Usd Book Value---47345000.0001880750.000-2617%85107000.000-156%62722600.000-175%51491537.300-192%
Usd Book Value Change Per Share---0.541-0.468-13%0.238-327%-0.084-85%-0.023-96%
Usd Book Value Per Share---0.8300.042-2087%1.545-154%1.140-173%0.936-189%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.628-0.661+5%-0.126-80%-0.396-37%-0.266-58%
Usd Free Cash Flow---30879000.000-30156000.000-2%-29687000.000-4%-22356850.000-28%-14142600.750-54%
Usd Free Cash Flow Per Share---0.541-0.534-1%-0.5390%-0.403-25%-0.255-53%
Usd Free Cash Flow To Equity Per Share---0.851-0.490-42%-0.114-87%-0.083-90%-0.002-100%
Usd Market Cap91990280.000+27%66764991.150410083617.648-84%390958690.000-83%447168559.530-85%378301464.765-82%
Usd Price Per Share1.670+30%1.1707.283-84%7.098-84%8.086-86%6.852-83%
Usd Profit---35828000.000-37309500.000+4%-7296250.000-80%-21718750.000-39%-14341982.950-60%
Usd Revenue--8055999.0007565749.750+6%6490750.000+24%4463199.950+80%2231599.975+261%
Usd Total Gains Per Share---0.541-0.468-13%0.238-327%-0.084-85%-0.023-96%
 EOD+6 -2MRQTTM+11 -22YOY+6 -275Y+8 -2510Y+7 -26

3.3 Fundamental Score

Let's check the fundamental score of Marinus Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.665
Price to Book Ratio (EOD)Between0-1-2.013
Net Profit Margin (MRQ)Greater than0-4.447
Operating Margin (MRQ)Greater than0-3.759
Quick Ratio (MRQ)Greater than11.899
Current Ratio (MRQ)Greater than12.283
Debt to Asset Ratio (MRQ)Less than11.544
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.411
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Marinus Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5056.003
Ma 20Greater thanMa 501.571
Ma 50Greater thanMa 1001.423
Ma 100Greater thanMa 2001.398
OpenGreater thanClose1.760
Total4/5 (80.0%)

4. In-depth Analysis

4.1 About Marinus Pharmaceuticals Inc

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

Fundamental data was last updated by Penke on 2024-09-12 05:33:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Marinus Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Marinus Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -444.7% means that $-4.45 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Marinus Pharmaceuticals Inc:

  • The MRQ is -444.7%. The company is making a huge loss. -2
  • The TTM is -494.6%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-444.7%TTM-494.6%+49.9%
TTM-494.6%YOY431.0%-925.6%
TTM-494.6%5Y-885.1%+390.4%
5Y-885.1%10Y-442.5%-442.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-444.7%-126.1%-318.6%
TTM-494.6%-194.5%-300.1%
YOY431.0%-207.8%+638.8%
5Y-885.1%-373.2%-511.9%
10Y-442.5%-473.1%+30.6%
4.3.1.2. Return on Assets

Shows how efficient Marinus Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Marinus Pharmaceuticals Inc to the Biotechnology industry mean.
  • -41.1% Return on Assets means that Marinus Pharmaceuticals Inc generated $-0.41 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Marinus Pharmaceuticals Inc:

  • The MRQ is -41.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -27.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-41.1%TTM-27.5%-13.6%
TTM-27.5%YOY-1.4%-26.1%
TTM-27.5%5Y-17.4%-10.1%
5Y-17.4%10Y-16.2%-1.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-41.1%-11.1%-30.0%
TTM-27.5%-11.9%-15.6%
YOY-1.4%-11.3%+9.9%
5Y-17.4%-13.2%-4.2%
10Y-16.2%-14.9%-1.3%
4.3.1.3. Return on Equity

Shows how efficient Marinus Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Marinus Pharmaceuticals Inc to the Biotechnology industry mean.
  • 0.0% Return on Equity means Marinus Pharmaceuticals Inc generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Marinus Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-77.4%+77.4%
TTM-77.4%YOY-9.6%-67.8%
TTM-77.4%5Y-73.9%-3.5%
5Y-73.9%10Y-46.5%-27.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--14.2%+14.2%
TTM-77.4%-16.0%-61.4%
YOY-9.6%-13.8%+4.2%
5Y-73.9%-19.1%-54.8%
10Y-46.5%-19.8%-26.7%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Marinus Pharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Marinus Pharmaceuticals Inc is operating .

  • Measures how much profit Marinus Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Marinus Pharmaceuticals Inc to the Biotechnology industry mean.
  • An Operating Margin of -375.9% means the company generated $-3.76  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Marinus Pharmaceuticals Inc:

  • The MRQ is -375.9%. The company is operating very inefficient. -2
  • The TTM is -442.3%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-375.9%TTM-442.3%+66.3%
TTM-442.3%YOY535.6%-977.9%
TTM-442.3%5Y-839.7%+397.4%
5Y-839.7%10Y-419.8%-419.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-375.9%-279.4%-96.5%
TTM-442.3%-329.9%-112.4%
YOY535.6%-230.4%+766.0%
5Y-839.7%-391.8%-447.9%
10Y-419.8%-499.6%+79.8%
4.3.2.2. Operating Ratio

Measures how efficient Marinus Pharmaceuticals Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 4.76 means that the operating costs are $4.76 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Marinus Pharmaceuticals Inc:

  • The MRQ is 4.759. The company is inefficient in keeping operating costs low. -1
  • The TTM is 5.416. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ4.759TTM5.416-0.657
TTM5.416YOY7.322-1.905
TTM5.4165Y13.145-7.728
5Y13.14510Y6.572+6.572
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.7592.759+2.000
TTM5.4163.146+2.270
YOY7.3223.336+3.986
5Y13.1455.133+8.012
10Y6.5726.571+0.001
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Marinus Pharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Marinus Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.28 means the company has $2.28 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Marinus Pharmaceuticals Inc:

  • The MRQ is 2.283. The company is able to pay all its short-term debts. +1
  • The TTM is 3.951. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ2.283TTM3.951-1.668
TTM3.951YOY7.413-3.462
TTM3.9515Y6.902-2.951
5Y6.90210Y9.185-2.284
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.2833.806-1.523
TTM3.9514.010-0.059
YOY7.4134.719+2.694
5Y6.9025.980+0.922
10Y9.1856.318+2.867
4.4.3.2. Quick Ratio

Measures if Marinus Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Marinus Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Quick Ratio of 1.90 means the company can pay off $1.90 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Marinus Pharmaceuticals Inc:

  • The MRQ is 1.899. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.113. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.899TTM4.113-2.214
TTM4.113YOY8.449-4.336
TTM4.1135Y7.142-3.029
5Y7.14210Y10.188-3.046
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8993.346-1.447
TTM4.1133.567+0.546
YOY8.4494.698+3.751
5Y7.1425.910+1.232
10Y10.1886.500+3.688
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Marinus Pharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Marinus Pharmaceuticals Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Marinus Pharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.54 means that Marinus Pharmaceuticals Inc assets are financed with 154.4% credit (debt) and the remaining percentage (100% - 154.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Marinus Pharmaceuticals Inc:

  • The MRQ is 1.544. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 1.073. The company is just not able to pay all its debts by selling its assets. -1
Trends
Current periodCompared to+/- 
MRQ1.544TTM1.073+0.470
TTM1.073YOY0.612+0.461
TTM1.0735Y0.537+0.536
5Y0.53710Y0.364+0.174
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5440.342+1.202
TTM1.0730.344+0.729
YOY0.6120.309+0.303
5Y0.5370.365+0.172
10Y0.3640.384-0.020
4.5.4.2. Debt to Equity Ratio

Measures if Marinus Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Marinus Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Marinus Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM2.969-2.969
TTM2.969YOY1.666+1.303
TTM2.9695Y2.344+0.626
5Y2.34410Y1.298+1.046
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.393-0.393
TTM2.9690.439+2.530
YOY1.6660.372+1.294
5Y2.3440.448+1.896
10Y1.2980.489+0.809
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Marinus Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced but always compare Marinus Pharmaceuticals Inc to the Biotechnology industry mean.
  • A PE ratio of -0.47 means the investor is paying $-0.47 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Marinus Pharmaceuticals Inc:

  • The EOD is -0.665. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.466. Based on the earnings, the company is expensive. -2
  • The TTM is -2.710. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.665MRQ-0.466-0.199
MRQ-0.466TTM-2.710+2.244
TTM-2.710YOY-1.955-0.755
TTM-2.7105Y-4.333+1.624
5Y-4.33310Y-8.520+4.187
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.665-2.310+1.645
MRQ-0.466-2.379+1.913
TTM-2.710-2.921+0.211
YOY-1.955-3.405+1.450
5Y-4.333-6.019+1.686
10Y-8.520-6.254-2.266
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Marinus Pharmaceuticals Inc:

  • The EOD is -0.772. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.541. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.515. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.772MRQ-0.541-0.231
MRQ-0.541TTM-3.515+2.974
TTM-3.515YOY-3.471-0.044
TTM-3.5155Y-3.088-0.427
5Y-3.08810Y-10.113+7.024
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.772-2.954+2.182
MRQ-0.541-3.175+2.634
TTM-3.515-3.483-0.032
YOY-3.471-4.594+1.123
5Y-3.088-8.064+4.976
10Y-10.113-8.708-1.405
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Marinus Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -1.41 means the investor is paying $-1.41 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Marinus Pharmaceuticals Inc:

  • The EOD is -2.013. Based on the equity, the company is expensive. -2
  • The MRQ is -1.410. Based on the equity, the company is expensive. -2
  • The TTM is 3.051. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD-2.013MRQ-1.410-0.603
MRQ-1.410TTM3.051-4.461
TTM3.051YOY5.314-2.263
TTM3.0515Y7.976-4.925
5Y7.97610Y8.055-0.079
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.0131.886-3.899
MRQ-1.4101.972-3.382
TTM3.0512.201+0.850
YOY5.3142.363+2.951
5Y7.9763.551+4.425
10Y8.0554.200+3.855
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Marinus Pharmaceuticals Inc.

4.8.1. Institutions holding Marinus Pharmaceuticals Inc

Institutions are holding 78.71% of the shares of Marinus Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-06-30TANG CAPITAL MANAGEMENT LLC8.7140.572480000048000000
2024-06-30Sofinnova Ventures7.53680.252441515762750523196.3183
2024-06-30Woodline Partners LP7.22460.044439796052792824235.3277
2024-06-30Suvretta Capital Management, LLC6.93490.16423820012-1288508-25.2227
2024-06-30Franklin Resources Inc6.34150.00133493143-110-0.0031
2024-06-30Vanguard Group Inc5.08850.00012802965-2955-0.1053
2024-06-30Lion Point Capital, LP3.83934.51082114827-4309-0.2033
2024-06-30Bleichroeder LP3.39930.6516187246300
2024-06-30BlackRock Inc3.39470.00011869949-2850612-60.3871
2024-06-30Jennison Associates LLC2.66740.00111469285-1496598-50.4605
2024-03-31Bain Capital Life Sciences Investors, LLC2.52961.01231393380-37678-2.6329
2024-06-30abrdn PLC1.9610.0024108019852762695.4855
2024-06-30Millennium Management LLC1.30450.00047185807185800
2024-06-30Ikarian Capital, LLC1.2820.143970615416822931.2737
2024-06-30Renaissance Technologies Corp1.12850.00126216256216250
2024-06-30Geode Capital Management, LLC1.12080.0001617395-597371-49.1758
2024-06-30Goldman Sachs Group Inc1.05670.0001582097445780327.0172
2024-06-30Susquehanna International Group, LLP0.9110.0001501797397907383.008
2024-03-31Morgan Stanley - Brokerage Accounts0.74080.0003408063-175732-30.1017
2024-06-30Northern Trust Corp0.73290.0001403711-65887-14.0305
Total 67.90887.358937406825+6703334+17.9%

4.9.2. Funds holding Marinus Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-07-31Franklin Biotechnology Discv A(acc)USD4.16130.1937229222700
2024-07-31Vanguard Total Stock Mkt Idx Inv3.1410.0001173019000
2024-07-31abrdn Healthcare Investors2.3230.1685127962352933770.5514
2024-07-31Franklin Biotechnology Discovery A2.17990.1786120078100
2024-06-30Jennison Health Sciences Equity1.53230.055844039-882349-51.1095
2024-07-31PGIM Jennison Health Sciences Z1.53230.064284403900
2024-07-31Vanguard Institutional Extnd Mkt Idx Tr1.47230.001181100000
2024-07-31abrdn Life Sciences Investors1.02430.168356423123431971.0247
2024-06-30Fidelity Small Cap Index0.98570.002454298200
2024-08-30iShares Biotechnology ETF0.66480.006536619000
2024-05-31International Biotechnology Ord0.52650.127329000000
2024-07-31Fidelity Extended Market Index0.3290.0006181236-128755-41.5351
2024-06-30Vanguard VIF Small Co Gr0.31080.01351712111712110
2023-12-31NT R2000 Growth Index Fund - NL0.28010.045315426449753.3325
2024-08-30iShares Micro-Cap ETF0.23210.019612784900
2024-06-30Northern Trust Russell 2000 Growth Index0.21840.005112030222781.9301
2024-06-30NT R2000 Growth Index Fund - L0.21840.005112030222781.9301
2024-06-30BlackRock Extended Equity Market K0.20480.001112814-109-0.0965
2024-06-30NT R2000 Index Fund - NL0.20050.0021110468-41710-27.4087
2024-07-31Fidelity Total Market Index0.17860.000198380-131-0.133
Total 21.71611.058111962128-108656-0.9%

5.3. Insider Transactions

Insiders are holding 0.959% of the shares of Marinus Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-08-05Christina ShaferSELL38201.14
2024-08-05Martha E ManningSELL36211.13
2024-08-05Scott BraunsteinSELL121451.13
2024-08-05Steven PfanstielSELL46571.13
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets87,083
Total Liabilities134,428
Total Stockholder Equity-47,345
 As reported
Total Liabilities 134,428
Total Stockholder Equity+ -47,345
Total Assets = 87,083

Assets

Total Assets87,083
Total Current Assets81,882
Long-term Assets5,201
Total Current Assets
Cash And Cash Equivalents 64,676
Net Receivables 3,435
Inventory 4,873
Other Current Assets 8,898
Total Current Assets  (as reported)81,882
Total Current Assets  (calculated)81,882
+/-0
Long-term Assets
Property Plant Equipment 4,420
Long-term Assets Other 781
Long-term Assets  (as reported)5,201
Long-term Assets  (calculated)5,201
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities35,867
Long-term Liabilities98,561
Total Stockholder Equity-47,345
Total Current Liabilities
Short-term Debt 15,177
Short Long Term Debt 11,550
Accounts payable 6,237
Other Current Liabilities 32,240
Total Current Liabilities  (as reported)35,867
Total Current Liabilities  (calculated)65,204
+/- 29,337
Long-term Liabilities
Long term Debt 45,075
Capital Lease Obligations 989
Long-term Liabilities  (as reported)98,561
Long-term Liabilities  (calculated)46,064
+/- 52,497
Total Stockholder Equity
Common Stock55
Retained Earnings -646,423
Other Stockholders Equity 599,023
Total Stockholder Equity (as reported)-47,345
Total Stockholder Equity (calculated)-47,345
+/-0
Other
Capital Stock55
Cash and Short Term Investments 64,676
Common Stock Shares Outstanding 57,064
Current Deferred Revenue-17,787
Liabilities and Stockholders Equity 87,083
Net Debt 31,218
Net Invested Capital 9,280
Net Working Capital 46,015
Short Long Term Debt Total 95,894



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-31
> Total Assets 
8,682
0
0
0
11,824
10,564
9,479
47,561
50,213
46,351
41,040
36,753
59,662
52,786
46,165
38,635
31,447
26,824
22,095
64,657
60,672
55,033
48,687
42,099
75,234
67,619
58,965
45,800
98,842
84,558
113,443
99,526
150,462
133,859
124,989
158,873
136,840
140,810
109,377
184,841
259,518
226,817
201,200
200,806
170,908
137,350
87,083
87,083137,350170,908200,806201,200226,817259,518184,841109,377140,810136,840158,873124,989133,859150,46299,526113,44384,55898,84245,80058,96567,61975,23442,09948,68755,03360,67264,65722,09526,82431,44738,63546,16552,78659,66236,75341,04046,35150,21347,5619,47910,56411,8240008,682
   > Total Current Assets 
0
0
0
0
11,799
10,542
9,449
47,544
50,148
45,794
40,135
34,860
57,767
51,716
44,404
37,123
30,299
25,676
20,959
43,547
54,370
53,718
47,407
40,817
73,940
62,872
54,193
41,141
94,134
79,998
109,035
95,172
140,155
129,798
120,924
153,491
122,927
135,071
101,091
177,006
240,551
199,201
194,609
195,040
165,246
131,276
81,882
81,882131,276165,246195,040194,609199,201240,551177,006101,091135,071122,927153,491120,924129,798140,15595,172109,03579,99894,13441,14154,19362,87273,94040,81747,40753,71854,37043,54720,95925,67630,29937,12344,40451,71657,76734,86040,13545,79450,14847,5449,44910,54211,7990000
       Cash And Cash Equivalents 
8,634
0
0
0
10,037
8,830
8,416
47,105
49,720
44,477
38,933
28,027
51,722
46,729
39,102
32,895
26,178
22,576
19,531
37,530
33,531
27,181
21,467
19,662
67,727
60,848
49,436
37,159
90,943
70,326
98,930
87,337
138,509
123,472
112,493
145,101
122,927
126,319
92,326
168,249
240,551
146,904
127,787
140,437
120,572
104,253
64,676
64,676104,253120,572140,437127,787146,904240,551168,24992,326126,319122,927145,101112,493123,472138,50987,33798,93070,32690,94337,15949,43660,84867,72719,66221,46727,18133,53137,53019,53122,57626,17832,89539,10246,72951,72228,02738,93344,47749,72047,1058,4168,83010,0370008,634
       Short-term Investments 
0
0
0
0
0
0
0
0
0
995
995
4,974
4,474
4,471
4,917
3,675
3,922
2,184
744
5,435
19,861
24,839
24,902
19,967
4,998
4,998
2,481
2,730
739
7,460
6,966
3,966
1,474
1,474
0
0
0
0
0
0
0
52,297
47,549
35,919
29,716
9,000
0
09,00029,71635,91947,54952,29700000001,4741,4743,9666,9667,4607392,7302,4814,9984,99819,96724,90224,83919,8615,4357442,1843,9223,6754,9174,4714,4744,974995995000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,646
2,650
4,201
3,532
3,186
2,489
3,000
3,398
6,348
11,693
5,234
4,281
3,799
3,513
3,435
3,4353,5133,7994,2815,23411,6936,3483,3983,0002,4893,1863,5324,2012,6501,64600000000000000000000000000000000
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-4,638
0
0
0
-557
0
0
104
77
37
2,674
2,736
2,413
5,783
4,873
4,8735,7832,4132,7362,674377710400-557000-4,63800000000000000000000000000000000
   > Long-term Assets 
0
0
0
0
25
23
30
17
65
557
905
1,893
1,895
1,070
1,761
1,512
1,148
1,148
1,136
21,110
6,302
1,315
1,280
1,282
1,294
4,747
4,772
4,659
4,708
4,560
4,408
4,354
10,307
4,061
4,065
5,382
13,913
5,739
8,286
7,835
18,967
27,616
6,591
5,766
5,662
6,074
5,201
5,2016,0745,6625,7666,59127,61618,9677,8358,2865,73913,9135,3824,0654,06110,3074,3544,4084,5604,7084,6594,7724,7471,2941,2821,2801,3156,30221,1101,1361,1481,1481,5121,7611,0701,8951,89390555765173023250000
       Property Plant Equipment 
9
0
0
0
16
14
11
9
44
42
39
36
31
779
1,017
1,016
1,148
1,148
1,136
1,172
1,338
1,315
1,280
1,282
1,294
2,216
2,381
2,337
2,265
2,186
2,105
2,026
1,945
1,894
1,984
2,650
2,499
2,989
5,561
5,520
4,236
4,037
3,938
3,909
4,843
5,235
4,420
4,4205,2354,8433,9093,9384,0374,2365,5205,5612,9892,4992,6501,9841,8941,9452,0262,1052,1862,2652,3372,3812,2161,2941,2821,2801,3151,3381,1721,1361,1481,1481,0161,017779313639424491114160009
       Long Term Investments 
0
0
0
0
0
0
0
0
0
496
496
1,489
1,488
248
744
496
0
0
0
19,938
4,964
0
0
0
0
0
2,481
0
739
0
0
0
1,474
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000001,47400073902,481000004,96419,9380004967442481,4881,489496496000000000
       Long-term Assets Other 
0
0
0
0
9
9
19
8
21
19
370
368
376
43
0
0
0
0
0
0
0
0
0
0
0
2,531
2,391
2,322
2,443
2,374
2,303
2,328
6,888
2,167
2,081
2,732
11,414
2,750
2,725
2,315
14,731
23,579
2,653
1,857
819
839
781
7818398191,8572,65323,57914,7312,3152,7252,75011,4142,7322,0812,1676,8882,3282,3032,3742,4432,3222,3912,53100000000000433763683701921819990000
> Total Liabilities 
4,500
0
0
0
2,366
2,026
5,003
3,335
9,059
11,621
11,156
11,095
12,741
12,219
13,834
11,942
9,968
7,576
5,806
2,557
2,664
1,908
3,667
6,977
6,909
9,874
12,380
11,729
11,073
13,245
12,298
12,103
13,263
18,525
29,930
80,379
83,354
100,405
104,574
102,837
143,518
141,732
143,861
146,269
154,143
153,784
134,428
134,428153,784154,143146,269143,861141,732143,518102,837104,574100,40583,35480,37929,93018,52513,26312,10312,29813,24511,07311,72912,3809,8746,9096,9773,6671,9082,6642,5575,8067,5769,96811,94213,83412,21912,74111,09511,15611,6219,0593,3355,0032,0262,3660004,500
   > Total Current Liabilities 
4,500
0
0
0
2,366
2,026
3,003
1,335
2,039
5,446
5,847
6,663
7,435
7,754
10,196
9,181
8,084
6,569
5,674
2,430
2,544
1,794
3,560
6,877
6,909
6,677
9,204
8,571
8,031
10,325
9,503
9,439
10,729
16,121
16,694
37,676
40,566
19,536
23,110
21,050
54,874
21,514
25,603
30,555
40,624
42,758
35,867
35,86742,75840,62430,55525,60321,51454,87421,05023,11019,53640,56637,67616,69416,12110,7299,4399,50310,3258,0318,5719,2046,6776,9096,8773,5601,7942,5442,4305,6746,5698,0849,18110,1967,7547,4356,6635,8475,4462,0391,3353,0032,0262,3660004,500
       Short-term Debt 
0
0
0
0
0
0
0
0
7,000
875
1,750
3,127
2,128
2,878
3,627
3,500
3,500
3,500
3,497
0
0
0
0
0
0
216
321
430
446
462
479
496
510
519
529
540
556
575
595
616
1,657
1,980
4,531
8,404
14,536
19,218
15,177
15,17719,21814,5368,4044,5311,9801,6576165955755565405295195104964794624464303212160000003,4973,5003,5003,5003,6272,8782,1283,1271,7508757,00000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
7,000
0
0
0
2,128
0
0
0
3,500
3,500
3,497
0
0
0
0
0
0
216
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,020
1,321
3,850
7,700
11,551
15,401
11,550
11,55015,40111,5517,7003,8501,3211,020000000000000002160000003,4973,5003,5000002,1280007,00000000000
       Accounts payable 
115
0
0
0
78
1,773
1,742
827
536
3,055
1,097
2,300
3,146
2,553
2,824
3,845
2,809
2,236
1,161
634
927
797
1,294
2,917
2,472
1,932
4,973
3,561
2,763
2,845
3,733
2,999
2,211
5,167
3,311
693
3,126
4,671
3,299
2,829
6,341
4,466
2,302
2,626
4,003
6,125
6,237
6,2376,1254,0032,6262,3024,4666,3412,8293,2994,6713,1266933,3115,1672,2112,9993,7332,8452,7633,5614,9731,9322,4722,9171,2947979276341,1612,2362,8093,8452,8242,5533,1462,3001,0973,0555368271,7421,77378000115
       Other Current Liabilities 
1,714
0
0
0
2,288
254
1,261
508
1,503
1,516
3,000
1,236
2,161
2,323
3,745
1,836
1,775
833
1,016
1,796
1,617
997
2,266
3,960
4,437
4,745
4,231
5,010
5,268
1
5,770
6,440
8,518
10,435
12,854
21,828
21,233
14,290
19,216
17,605
46,876
15,068
19,451
1,901
22,085
17,415
32,240
32,24017,41522,0851,90119,45115,06846,87617,60519,21614,29021,23321,82812,85410,4358,5186,4405,77015,2685,0104,2314,7454,4373,9602,2669971,6171,7961,0168331,7751,8363,7452,3232,1611,2363,0001,5161,5035081,2612542,2880001,714
   > Long-term Liabilities 
0
0
0
0
0
0
2,000
2,000
7,020
6,175
5,309
4,432
5,306
4,465
3,638
2,761
1,884
1,007
132
127
120
114
107
100
0
3,197
3,176
3,158
3,042
2,920
2,795
2,664
2,534
2,404
13,236
42,703
42,788
80,869
81,464
81,787
88,644
120,218
118,258
115,714
113,519
111,026
98,561
98,561111,026113,519115,714118,258120,21888,64481,78781,46480,86942,78842,70313,2362,4042,5342,6642,7952,9203,0423,1583,1763,19701001071141201271321,0071,8842,7613,6384,4655,3064,4325,3096,1757,0202,0002,000000000
       Long term Debt Total 
0
0
0
0
0
0
2,000
2,000
7,000
6,125
5,250
4,375
5,250
4,363
3,489
2,616
1,743
870
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10,970
40,579
40,809
69,927
70,350
70,780
71,018
71,498
68,136
0
0
0
0
000068,13671,49871,01870,78070,35069,92740,80940,57910,97000000000000000008701,7432,6163,4894,3635,2504,3755,2506,1257,0002,0002,000000000
       Warrants
0
0
0
0
0
0
70,340
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
28,200
28,200
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000028,20028,20000000000000000000000070,340000000
       Other Liabilities 
0
0
0
0
0
0
0
0
20
50
59
57
56
102
149
145
141
137
132
127
120
114
107
100
0
3,197
0
0
3,042
0
2,795
0
0
2,404
0
0
0
9,113
11,114
9,499
16,285
0
17,182
0
0
0
0
000017,182016,2859,49911,1149,1130002,404002,79503,042003,1970100107114120127132137141145149102565759502000000000
> Total Stockholder Equity
4,182
0
0
0
9,458
8,538
4,476
44,225
41,154
34,730
29,884
25,658
46,921
40,567
32,331
26,693
21,479
19,248
16,289
62,100
58,008
53,125
45,020
35,122
68,325
57,745
46,585
34,071
87,769
71,313
101,145
87,423
137,199
115,334
95,059
78,494
53,486
40,405
4,803
82,004
116,000
85,085
57,339
54,537
16,765
-16,434
-47,345
-47,345-16,43416,76554,53757,33985,085116,00082,0044,80340,40553,48678,49495,059115,334137,19987,423101,14571,31387,76934,07146,58557,74568,32535,12245,02053,12558,00862,10016,28919,24821,47926,69332,33140,56746,92125,65829,88434,73041,15444,2254,4768,5389,4580004,182
   Common Stock
0
0
0
0
0
8
1
14
14
14
14
14
19
20
20
20
20
22
23
40
41
41
41
41
53
53
53
53
87
87
123
31
37
37
37
37
37
37
37
37
50
50
51
55
55
55
55
5555555551505037373737373737373112387875353535341414141402322202020201914141414141800000
   Retained Earnings Total Equity0000-497,185-465,251-430,521-396,209-469,499-430,066-410,705-382,400-362,893-339,070-311,929-294,460-278,801-263,126-235,600-220,165-206,359-193,936-181,453-171,341-160,231-150,726-144,727-139,989-135,819-131,267-125,829-119,814-113,351-104,402-97,186-89,573-84,611-79,343-72,336-68,729-67,061000000
   Accumulated Other Comprehensive Income 
0
0
0
0
-429
-431
-434
-436
-356
-358
-362
-364
-349
-349
0
0
-358
-358
0
-18
-96
-107
-69
-28
-2
-573
-650
1
-812
28
27
11
0
0
0
0
-4,302
0
0
0
0
74
-114
-71
-20
0
0
00-20-71-114740000-4,3020000112728-8121-650-573-2-28-69-107-96-180-358-35800-349-349-364-362-358-356-436-434-431-4290000
   Capital Surplus 
0
0
0
0
0
0
1,196
112,941
113,476
114,059
114,481
115,217
144,088
144,949
145,662
146,487
147,288
150,493
152,085
202,067
202,790
203,917
205,279
206,450
249,727
251,628
252,891
254,182
295,056
306,124
371,051
373,143
444,622
449,898
453,613
456,555
459,852
466,132
470,222
474,133
542,428
546,169
554,587
0
0
0
0
0000554,587546,169542,428474,133470,222466,132459,852456,555453,613449,898444,622373,143371,051306,124295,056254,182252,891251,628249,727206,450205,279203,917202,790202,067152,085150,493147,288146,487145,662144,949144,088115,217114,481114,059113,476112,9411,196000000
   Treasury Stock00000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
1,549
72,700
1,629
113,377
113,832
114,417
114,843
115,581
144,437
144,949
145,662
146,487
147,646
150,493
152,085
202,049
203,178
203,810
205,210
206,422
250,335
252,201
253,541
254,915
295,868
306,124
371,051
373,143
444,622
449,898
453,613
456,555
464,154
466,132
470,222
474,133
542,428
546,169
554,587
584,710
588,656
594,106
599,023
599,023594,106588,656584,710554,587546,169542,428474,133470,222466,132464,154456,555453,613449,898444,622373,143371,051306,124295,868254,915253,541252,201250,335206,422205,210203,810203,178202,049152,085150,493147,646146,487145,662144,949144,437115,581114,843114,417113,832113,3771,62972,7001,5490000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue30,989
Cost of Revenue-2,485
Gross Profit28,50428,504
 
Operating Income (+$)
Gross Profit28,504
Operating Expense-159,989
Operating Income-131,485-131,485
 
Operating Expense (+$)
Research Development98,837
Selling General Administrative60,452
Selling And Marketing Expenses0
Operating Expense159,989159,289
 
Net Interest Income (+$)
Interest Income8,110
Interest Expense-16,895
Other Finance Cost-608
Net Interest Income-8,177
 
Pretax Income (+$)
Operating Income-131,485
Net Interest Income-8,177
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-142,943-120,027
EBIT - interestExpense = -148,380
-142,943
-124,510
Interest Expense16,895
Earnings Before Interest and Taxes (EBIT)-131,485-126,048
Earnings Before Interest and Taxes (EBITDA)-130,934
 
After tax Income (+$)
Income Before Tax-142,943
Tax Provision-99
Net Income From Continuing Ops-133,948-143,042
Net Income-141,405
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses162,474
Total Other Income/Expenses Net-11,4588,177
 

Technical Analysis of Marinus Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Marinus Pharmaceuticals Inc. The general trend of Marinus Pharmaceuticals Inc is BULLISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Marinus Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (28.6%) Bearish trend (-28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Marinus Pharmaceuticals Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 1.97 < 3.465 < 5.5704.

The bearish price targets are: 1.635 > 1.585 > 1.54.

Tweet this
Marinus Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Marinus Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 9/14.
The longshort score for the Moving Averages is 4/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Marinus Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Marinus Pharmaceuticals Inc. The current macd is 0.10310597.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Marinus Pharmaceuticals Inc price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Marinus Pharmaceuticals Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Marinus Pharmaceuticals Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Marinus Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartMarinus Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Marinus Pharmaceuticals Inc. The current adx is 33.21.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Marinus Pharmaceuticals Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Marinus Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Marinus Pharmaceuticals Inc. The current sar is 1.97.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Marinus Pharmaceuticals Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Marinus Pharmaceuticals Inc. The current rsi is 56.00. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending down: The RSI is trending down. -1
Marinus Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartMarinus Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Marinus Pharmaceuticals Inc. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Marinus Pharmaceuticals Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Marinus Pharmaceuticals Inc Daily Stochastic Oscillator ChartMarinus Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Marinus Pharmaceuticals Inc. The current cci is 56.02.

Marinus Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartMarinus Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Marinus Pharmaceuticals Inc. The current cmo is 6.54015637.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Marinus Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartMarinus Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Marinus Pharmaceuticals Inc. The current willr is -50.84745763.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Marinus Pharmaceuticals Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Marinus Pharmaceuticals Inc Daily Williams %R ChartMarinus Pharmaceuticals Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Marinus Pharmaceuticals Inc.

Marinus Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Marinus Pharmaceuticals Inc. The current atr is 0.12419285.

Marinus Pharmaceuticals Inc Daily Average True Range (ATR) ChartMarinus Pharmaceuticals Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Marinus Pharmaceuticals Inc. The current obv is -59,160,774.

Marinus Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartMarinus Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Marinus Pharmaceuticals Inc. The current mfi is 70.50.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Marinus Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartMarinus Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Marinus Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-05-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-14STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-05-16CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-05-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-29RSI LONG ENTRY SHORT CLOSE30 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-05-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-03RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-05STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-06-06CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-06-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-06-11WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-06-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-06-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-06-18WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-06-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-26STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-06-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-01RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-07-02STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-11CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-07-15WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-07-16CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-07-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-22CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-07-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-30CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-31CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-06RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-14CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-15STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-16CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-08-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-08-21WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-08-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-29CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-08-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-09-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-09-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-09-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-09-13STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-16BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-09-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-19STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-23RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-09-24STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-25RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-30STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-10-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside

6.3. Candlestick Patterns

Marinus Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Marinus Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5056.003
Ma 20Greater thanMa 501.571
Ma 50Greater thanMa 1001.423
Ma 100Greater thanMa 2001.398
OpenGreater thanClose1.760
Total4/5 (80.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Marinus Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on Marinus Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Marinus Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Marinus Pharmaceuticals Inc

I send you an email if I find something interesting about Marinus Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Marinus Pharmaceuticals Inc.

Receive notifications about Marinus Pharmaceuticals Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.